Stock 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
29.84 CNY +1.22% Intraday chart for Beijing Konruns Pharmaceutical Co.,Ltd. +2.54% -21.64%
Apr. 25 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Konruns Pharma Enrolls First Subject in Phase 3 Study of Cancer Drug
MT
Beijing Konruns Pharmaceutical Gets Nod to Test KC1036 Tablets as Esophagus Cancer Treatment
MT
Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment
MT
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023.
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2022.
CI
Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
CI
Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback announced on January 21, 2021, has expired with 2,273,523 shares, representing 1.44% for CNY 79.31 million.
CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
CI
Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603590 Stock
  4. News Beijing Konruns Pharmaceutical Co.,Ltd.